Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology

Volumn 66, Issue 7, 2006, Pages 983-995

  Pahwa, R ^a   Factor, S A ^b   Lyons, K E ^a   Ondo, W G ^c   Gronseth, G ^a   Bronte Stewart, H ^d   Hallett, M ^e   Miyasaki, J ^f   Stevens, J ^g   Weiner, W J ^h  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g Fort Wayne Neurological Center   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; BUPIDINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; IDAZOXAN; ISTRADEFYLLINE; LEVODOPA; MEMANTINE; MONOAMINE OXIDASE B INHIBITOR; NABILONE; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; REMACEMIDE; RILUZOLE; ROPINIROLE; SARIZOTAN; SELEGILINE; TALAMPANEL; TOLCAPONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGRANULOCYTOSIS; ANOREXIA; ARTICLE; ASTHENIA; BALANCE IMPAIRMENT; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; CONFUSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DYSKINESIA; EMBASE; EVIDENCE BASED MEDICINE; FIBROSIS; FOOT EDEMA; GLOBUS PALLIDUS; HALLUCINATION; HUMAN; HYPERSALIVATION; INSOMNIA; LIVER TOXICITY; MEDICAL LITERATURE; MEDLINE; MELANOMA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MYOCARDITIS; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUBTHALAMIC NUCLEUS; SURGICAL TECHNIQUE; SYNCOPE; THALAMUS; TIME SERIES ANALYSIS; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION; HEALTH CARE QUALITY; NEUROLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; STANDARD; UNITED STATES;

DYSKINESIAS; HUMANS; MOVEMENT DISORDERS; NEUROLOGY; PARKINSON DISEASE; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES;

EID: 33646076457     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000215250.82576.87     Document Type: Article

References (59)

1. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005;20:224-230.
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
3. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
4. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
5. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000;342:461-468.
6. Lyons KE, Pahwa R. Deep brain stimulation in Parkinson's disease. Curr Neurol Neurosci Rep 2004;4:290-295.
7. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
8. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
9. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065.
10. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996;19:234-245.
11. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:1057-1062.
12. Dewey RB, Jr., Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385-1392.
13. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996;243:68-72.
14. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202-212.
15. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988;11:45-55.
16. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004;19:426-432.
17. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248.
18. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
19. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the "wearing- off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071.
20. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428.
21. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
22. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
23. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309-1314.
24. Fenelon G, Gimenez-Roldan S, Montastruc JL, et al. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm 2003;110:239-251.
25. Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000;57:263-267.
26. Jankovic J, Schwartz K, Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord 1989;4:303-309.
27. Hutton JT, Morris JL, Roman GC, Imke SC, Elias JW. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. Arch Neurol 1988;45:861-864.
28. Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 1988;63:876-886.
29. Lieberman A, Gopinathan G, Miller E, Neophytides A, Baumann G, Chin L. Randomized double-blind cross-over study of Sinemet-controlled release (CR4 50/200) versus Sinemet 25/100 in Parkinson's disease. Eur Neurol 1990;30:75-78.
30. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-788.
31. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002;109:489-502.
32. Agid Y, Oertel W, Factor S. Entacapone to tolcapone switch study: multicenter, double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 2005;20(suppl 10):S94.
33. Koller W, Lees A, Doder M, Hely M. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord 2001;16:858-866.
34. Snow BJ, Macdonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-85.
35. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004;62:381-388.
36. Deep Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-963.
37. Ostergaard K, Sunde N, Dupont E. Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord 2002;17:693-700.
38. Pahwa R, Wilkinson SB, Overman J, Lyons KE. Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. J Neurosurg 2003;99:71-77.
39. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial. Neurology 2004;62:201-207.
40. Figueiras-Mendez R, Regidor I, Riva-Meana C, Magarinos-Ascone CM. Further supporting evidence of beneficial subthalamic stimulation in Parkinson's patients. Neurology 2002;58:469-470.
41. Vesper J, Klostermann F, Stockhammer F, Funk T, Brock M. Results of chronic subthalamic nucleus stimulation for Parkinson's disease: a 1-year follow-up study. Surg Neurol 2002;57:306-311; discussion 311-303.
42. Welter MT, Houeto JL, Tezenas du Montcel S, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002;125:575-583.
43. Doshi PK, Chhaya NA, Bhatt MA. Bilateral subthalamic nucleus stimulation for Parkinson's disease. Neurol India 2003;51:43-48.
44. Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 2003;18:1332-1337.
45. Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 2003;99:489-495.
46. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-1934.
47. Romito LM, Scerrati M, Contarino MF, Iacoangeli M, Bentivoglio AR, Albanese A. Bilateral high frequency subthalamic stimulation in Parkinson's disease: long-term neurological follow-up. J Neurosurg Sci 2003;47:119-128.
48. Krause M, Fogel W, Mayer P, Kloss M, Tronnier V. Chronic inhibition of the subthalamic nucleus in Parkinson's disease. J Neurol Sci 2004;219:119-124.
49. Visser-Vandewalle V, Temel Y, van der Linden C, Ackermans L, Beuls E. Deep brain stimulation in movement disorders. The applications reconsidered. Acta Neurol Belg 2004;104:33-36.
50. Ogura M, Nakao N, Nakai E, Uematsu Y, Itakura T. The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease. J Neurosurg 2004;100:997-1001.
51. Visser-Vandewalle V, van der Linden C, Temel Y, Nieman F, Celik H, Beuls E. Long-term motor effect of unilateral pallidal stimulation in 26 patients with advanced Parkinson disease. J Neurosurg 2003;99:701-707.
52. Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996;84:203-214.
53. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 1997;42:292-299.
54. Hariz MI, Shamsgovara P, Johansson F, Hariz G, Fodstad H. Tolerance and tremor rebound following long-term chronic thalamic stimulation for Parkinsonian and essential tremor. Stereotact Funct Neurosurg 1999;72:208-218.
55. Limousin P, Speelman JD, Gielen F, Janssens M. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry 1999;66:289-296.
56. Beric A, Kelly PJ, Rezai A, et al. Complications of deep brain stimulation surgery. Stereotact Funct Neurosurg 2001;77:73-78.
57. Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM. Long-term hardware-related complications of deep brain stimulation. Neurosurgery 2002;50:1268-1274; discussion 1274-1266.
58. Umemura A, Jaggi JL, Hurtig HI, et al. Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg 2003;98:779-784.
59. Lyons KE, Wilkinson SB, Overman J, Pahwa R. Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures. Neurology 2004;63:612-616.